# psoriasis - grok-4.6

- Benchmark system: raw
- Repeat: 2
- Task type: DISEASE-STATE
- Tissue / sample source: lesional skin
- Comparison or endpoint: psoriatic lesional skin versus normal control skin
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: disabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: xAI / grok-4.6
- Message SHA-256: d1a33d3f606c81814c4fb94a6c63c8f1abebd3bde37d769e82eae4772d8ff873
- Response HTTP status: 200
- Prompt tokens: 4061
- Completion tokens: 3257
- Reasoning tokens: 
- Total tokens: 7318
- API requests reported: 
- Elapsed seconds: 42.367
- Final benchmark system: raw; file rank 2/5; original repeat 2; model vendor: xAI

---
**Overall biological interpretation**  
Psoriatic lesional skin exhibits a massive, highly significant transcriptional reprogramming dominated by keratinocyte-driven innate immune activation, epidermal barrier dysregulation, and chemokine-mediated leukocyte recruitment. The top 50 differentially expressed genes are overwhelmingly upregulated (log2FC 2–11), reflecting the cardinal pathological features of psoriasis: parakeratotic hyperproliferation, defective cornified envelope formation, overproduction of antimicrobial peptides and S100-alarmins, and IL-36/IL-19-family signaling that amplifies Th17-like inflammation. Downregulation is limited to a small set of genes (BTC, SAPCD1, UGT3A2, CYP2W1, etc.), consistent with partial loss of terminal differentiation and metabolic reprogramming. Collectively, these changes indicate a coordinated shift from homeostatic keratinocyte function toward a hyper-inflammatory, barrier-compromised state in which innate immune signals dominate over adaptive immunity.

**Core biological programs**  

1. **Cornified envelope and epidermal barrier assembly**  
   Direction: strongly upregulated.  
   Major genes: SPRR2A/B/D/E/F, SPRR3, LCE3A/D, GJB2, GJB6, MPZL2, KRT6A.  
   Pathway: Reactome “Cornified envelope” (R-HSA-6807048) and GO:0031589 “cornified envelope”.  
   Explanation: SPRRs and LCEs form the cross-linked lipid envelope that protects the stratum corneum; their extreme upregulation (log2FC 4–7) reflects the hyperproliferative, parakeratotic state and defective terminal differentiation.  
   Evidence strength: direct (multiple independent genes in dataset) + literature (SPRRs/LCEs upregulated in lesional psoriasis).  
   Limitations: may partly reflect compensatory attempt at barrier repair rather than primary defect.

2. **IL-36/IL-19-family keratinocyte activation and IL-17 axis amplification**  
   Direction: strongly upregulated.  
   Major genes: IL36A, IL36G, IL36RN, IL19, IL20, IL26, IL36A/IL36G as top hits.  
   Pathway: KEGG “IL-36 signaling” and Reactome “Interleukin-36 signaling”.  
   Explanation: IL-36 cytokines are master drivers of psoriasis; IL36A/G are the most upregulated genes in the dataset and signal via IL-1Rrp2/ST2 to induce CXCL8, defensins, and S100 genes in keratinocytes.  
   Evidence strength: direct (multiple IL-36 genes) + strong external (IL36RA loss-of-function mutations protect against psoriasis).  
   Limitations: dataset lacks receptor subunits (IL1RL2/ST2), so signaling directionality inferred.

3. **Antimicrobial peptide and S100-alarmins innate immune response**  
   Direction: strongly upregulated.  
   Major genes: DEFB4A/B, DEFB103A/B, S100A7/A8/A12/A7A.  
   Pathway: Hallmark “Inflammatory Response” and GO:0006955 “immune response”.  
   Explanation: Beta-defensins and S100 proteins form a dual antimicrobial + damage-associated molecular pattern (DAMP) response; S100A8/A9 (calprotectin) and DEFB4A are classic psoriasis markers whose extreme induction drives neutrophil chemotaxis and keratinocyte proliferation.  
   Evidence strength: direct (multiple genes) + literature (S100/DEFB4A highly diagnostic and functionally validated).

4. **Chemokine-mediated leukocyte recruitment**  
   Direction: upregulated.  
   Major genes: CXCL13, CXCR2, HPSE.  
   Pathway: Reactome “Chemokine signaling pathway” and GO:0050900 “leukocyte migration”.  
   Explanation: CXCL13 recruits CXCR4/CXCR5-expressing lymphocytes; HPSE remodels extracellular matrix to facilitate infiltration.  
   Evidence strength: direct (CXCL13/CXCR2) + established psoriasis literature.

5. **Metabolic and redox reprogramming**  
   Direction: mixed but dominated by upregulation of catabolic enzymes.  
   Major genes: KYNU, AKR1B10/15, VNN3P, PLA2G4D/E, TCN1.  
   Pathway: KEGG “Tryptophan metabolism” and GO:0006082 “metabolic process”.  
   Explanation: KYNU and AKR1B enzymes generate kynurenic acid and retinol metabolites that modulate inflammation and oxidative stress; VNN3P produces pantetheine, linking to oxidative stress.  
   Evidence strength: direct (multiple genes) + literature (AKR1B10/15 and KYNU altered in inflammatory skin disease).

**Key genes and interaction modules** (selected for mechanistic prominence)  

- **S100A7 / S100A8 / S100A12**: strongest single-gene signals; direct transcriptional targets of IL-36 and NF-κB; form heterodimers that act as DAMPs and neutrophil chemoattractants; co-expression module with DEFB4A.  
- **IL36A / IL36G**: most upregulated genes; initiate feed-forward loop amplifying IL-36 and IL-17 signaling; regulatory interaction with IL36RN (decoy receptor).  
- **DEFB4A / DEFB103A/B**: antimicrobial peptides; induced by IL-36/STAT3; direct physical interaction possible with S100A8 (calprotectin complex).  
- **SPRR2A / SPRR2B / SPRR3**: core cornified envelope components; co-expression with KRT6A; regulatory interaction with GJB2 (gap junction protein).  
- **CXCL13 / CXCR2**: chemokine-receptor axis; indirect via IL-36-induced CXCL13; pathway co-membership in chemotaxis.  
- **HPSE**: extracellular matrix remodeler; regulatory interaction with CXCL13; promotes leukocyte infiltration.  
- **KYNU**: kynurenine pathway enzyme; links tryptophan catabolism to aryl hydrocarbon receptor signaling; indirect relationship to inflammatory gene set.  
- **VNN3P**: vanin-3; produces oxidative-stress metabolites; co-expression with S100 genes.  
- **GJB2 / GJB6**: gap-junction proteins; disrupted in inflammatory skin disorders; pathway co-membership with SPRRs in barrier assembly.  
- **BTC**: downregulated; EGFR ligand normally suppresses inflammation; loss may exacerbate keratinocyte hyperproliferation.

**Validation priorities**  

1. **Mechanistic hypothesis – IL36A/IL36G as proximal drivers**  
   Why: top two most significant genes in entire dataset.  
   Evidence: direct (expression) + external (IL36RA mutations protect against psoriasis).  
   Next step: CRISPR activation/repression in primary human keratinocytes + RNA-seq.  
   Conclusion level: Supported hypothesis.

2. **Therapeutic target – S100A8/A9 (calprotectin)**  
   Why: dual role in keratinocyte activation and neutrophil chemotaxis; clinically validated antibody (ABT-981).  
   Evidence: direct + literature.  
   Next step: tissue-specific blockade in patient-derived xenografts.  
   Conclusion level: Supported hypothesis.

3. **Biomarker – SPRR2A / DEFB4A gene-expression signature**  
   Why: extreme magnitude and keratinocyte specificity.  
   Evidence: direct (dataset) + diagnostic literature.  
   Next step: qPCR or NanoString validation in independent cohorts.  
   Conclusion level: Supported hypothesis.

4. **Interaction / network hypothesis – IL-36 → S100 → defensin axis**  
   Why: feed-forward amplification loop.  
   Evidence: co-expression + literature.  
   Next step: ChIP-seq for STAT3/IRF8 at S100A7/DEFB4 promoters in IL-36-stimulated keratinocytes.  
   Conclusion level: Exploratory hypothesis.

5. **Confounding or composition check – immune-cell infiltration**  
   Why: bulk RNA-seq cannot distinguish keratinocyte vs. infiltrating leukocyte contributions.  
   Evidence: indirect (CXCL13/CXCR2).  
   Next step: single-nucleus RNA-seq or spatial transcriptomics in matched biopsies.  
   Conclusion level: Exploratory hypothesis.

**Evidence grounding**  
All core programs rest primarily on direct evidence from the input dataset (multiple independent genes with extreme statistical significance). Pathway/ ontology support comes from Reactome, KEGG, and GO annotations that pre-date the current dataset. Disease-association and expression evidence derive from published psoriasis transcriptomes and functional studies. Protein-interaction evidence is strongest for S100–defensin and IL-36–CXCL13 modules (literature). No single source is exclusively relied upon; the multi-gene convergence across programs provides independent reinforcement. No conflicting evidence was encountered.

**Limitations and alternative explanations**  
1. Bulk microarray cannot resolve keratinocyte vs. immune-cell contributions; many “keratinocyte” genes may partly reflect neutrophil infiltration.  
2. Lesional skin is heterogeneous in disease severity and may include treatment effects (even if not explicitly stated).  
3. Platform and batch effects possible in older microarray datasets.  
4. Downregulated genes (BTC, SAPCD1) may represent loss of homeostatic signals rather than primary defects.  
5. Correlation vs. causation: extreme upregulation of SPRRs/LCEs may be compensatory rather than causal.  
These possibilities can be addressed by single-cell or spatial transcriptomics and by comparison with matched uninvolved skin from the same patients.
